You are here: Industry Insights > Teijin Pharma

News List

Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression prnasia
April 25, 2021
Jolly Good Inc. and Teijin Pharma Ltd. have signed a business partnership agreement to develop VR digital therapeutics for Major Depressive Disorder (MDD).
Takeda sells Japan’s non-core products portfolio to Teijin Pharma pharmaceutical-technology
April 02, 2021
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn pharmaceutical-technology
March 02, 2021
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn).
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration prnasia
December 21, 2020
Teijin Pharma Limited, the core company of the Teijin Group's healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd., a clinical-stage biotechnology company based in Nanjing, China, jointly announced that they have ...